Cronos Group Inc.
TSX:CRON.TODrug Manufacturers - Specialty & Generic
-$0.01 today
- Market cap
- $1.67B
- Beta
- 1.25
- P/E (TTM)
- -488.1
- EPS (TTM)
- -$0.01
Volume 0.15M
Average 0.19M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Cronos Group Inc.
TSX:CRON.TO
Intrinsic Alpha fair value
Locked
Current Price
$4.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +19.4% | +16.0% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +19.4% over three years. Forward estimates point to Revenue at +16.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Extendicare Inc. TSX:EXE.TO | $2.88B | $30.34 | Overvalued | 26.4 | +41.85% |
Sienna Senior Living Inc. TSX:SIA.TO | $2.24B | $20.20 | Undervalued | 48.5 | +2.61% |
Knight Therapeutics Inc. TSX:GUD.TO | $1.18B | $12.06 | Undervalued | 164.6 | +88.58% |
WELL Health Technologies Corp. TSX:WELL.TO | $982.84M | $3.84 | Undervalued | 41.6 | -5.37% |
Tilray Brands, Inc. TSX:TLRY.TO | $514.30M | $3.48 | Not rated | -0.3 | -76.25% |
Continue the stock analysis
Jump to another research area for this company.